MedTrace Logo

Vismodegib in Treating Patients With Advanced Chondrosarcomas

NCT01267955 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-04-13

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well vismodegib works in treating patients with chondrosarcomas that have spread to other places in the body and usually cannot be cured or controlled with treatment. Drugs used in chemotherapy, such as vismodegib, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Conditions

  • Clear Cell Chondrosarcoma
  • Dedifferentiated Chondrosarcoma
  • Locally Advanced Chondrosarcoma
  • Mesenchymal Chondrosarcoma
  • Metastatic Chondrosarcoma
  • Primary Central Chondrosarcoma
  • Unresectable Primary Central Chondrosarcoma

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacogenomic Study

Correlative studies

DRUG

Vismodegib

Given PO

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Antoine Italiano · Institut Bergonie Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-21
Primary Completion
2018-06-30
Completion
2026-07-21
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01267955 on ClinicalTrials.gov